Literature DB >> 24399855

Regulation of UDP-glucuronosyltransferase 1A1 expression and activity by microRNA 491-3p.

Douglas F Dluzen1, Dongxiao Sun, Anna C Salzberg, Nate Jones, Ryan T Bushey, Gavin P Robertson, Philip Lazarus.   

Abstract

The UDP-glucuronosyltransferase (UGT) 1A enzymes are involved in the phase II metabolism of many important endogenous and exogenous compounds. The nine UGT1A isoforms exhibit high interindividual differences in expression, but their epigenetic regulation is not well understood. The purpose of the present study was to examine microRNA (miRNA) regulation of hepatic UGT1A enzymes and determine whether or not that regulation impacts enzymatic activity. In silico analysis identified miRNA 491-3p (miR-491-3p) as a potential regulator of the UGT1A gene family via binding to the shared UGT1A 3'-untranslated region common to all UGT1A enzymes. Transfection of miR-491-3p mimic into HuH-7 cells significantly repressed UGT1A1 (P < 0.001), UGT1A3 (P < 0.05), and UGT1A6 (P < 0.05) mRNA levels. For UGT1A1, this repression correlated with significantly reduced metabolism of raloxifene into raloxifene-6-glucuronide (ral-6-gluc; P < 0.01) and raloxifene-4'-glucuronide (ral-4'-gluc; P < 0.01). In HuH-7 cells with repressed miR-491-3p expression, there was a significant increase (~80%; P < 0.01) in UGT1A1 mRNA and a corresponding increase in glucuronidation of raloxifene into ral-6-gluc (50%; P < 0.05) and ral-4'-gluc (22%; P < 0.01). Knockdown of endogenous miR-491-3p in HepG2 cells did not significantly alter UGT1A1 mRNA levels but did increase the formation of ral-6-gluc (50%; P < 0.05) and ral-4'-gluc (34%; P < 0.001). A significant inverse correlation between miR-491-3p expression and both UGT1A3 (P < 0.05) and UGT1A6 (P < 0.01) mRNA levels was observed in a panel of normal human liver specimens, with a significant (P < 0.05) increase in UGT1A3 and UGT1A6 mRNA levels observed in miR-491-3p nonexpressing versus expressing liver specimens. These results suggest that miR-491-3p is an important factor in regulating the expression of UGT1A enzymes in vivo.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24399855      PMCID: PMC3935146          DOI: 10.1124/jpet.113.210658

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  60 in total

1.  Quantification of Hepatic UDP glucuronosyltransferase 1A splice variant expression and correlation of UDP glucuronosyltransferase 1A1 variant expression with glucuronidation activity.

Authors:  Nathan R Jones; Dongxiao Sun; Willard M Freeman; Philip Lazarus
Journal:  J Pharmacol Exp Ther       Date:  2012-06-01       Impact factor: 4.030

2.  Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7.

Authors:  F Innocenti; L Iyer; J Ramírez; M D Green; M J Ratain
Journal:  Drug Metab Dispos       Date:  2001-05       Impact factor: 3.922

3.  Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance.

Authors:  Daniel C Kemp; Peter W Fan; Jeffrey C Stevens
Journal:  Drug Metab Dispos       Date:  2002-06       Impact factor: 3.922

4.  Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities.

Authors:  Sumio Ohtsuki; Olaf Schaefer; Hirotaka Kawakami; Tae Inoue; Stephanie Liehner; Asami Saito; Naoki Ishiguro; Wataru Kishimoto; Eva Ludwig-Schwellinger; Thomas Ebner; Tetsuya Terasaki
Journal:  Drug Metab Dispos       Date:  2011-10-12       Impact factor: 3.922

5.  Mammalian microRNAs predominantly act to decrease target mRNA levels.

Authors:  Huili Guo; Nicholas T Ingolia; Jonathan S Weissman; David P Bartel
Journal:  Nature       Date:  2010-08-12       Impact factor: 49.962

6.  Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases.

Authors:  Dongxiao Sun; Arun K Sharma; Ryan W Dellinger; Andrea S Blevins-Primeau; Renee M Balliet; Gang Chen; Telih Boyiri; Shantu Amin; Philip Lazarus
Journal:  Drug Metab Dispos       Date:  2007-07-30       Impact factor: 3.922

7.  Quantitative analysis of UDP-glucuronosyltransferase (UGT) 1A and UGT2B expression levels in human livers.

Authors:  Takeshi Izukawa; Miki Nakajima; Ryoichi Fujiwara; Hiroyuki Yamanaka; Tatsuki Fukami; Masataka Takamiya; Yasuhiro Aoki; Shin-ichi Ikushiro; Toshiyuki Sakaki; Tsuyoshi Yokoi
Journal:  Drug Metab Dispos       Date:  2009-05-13       Impact factor: 3.922

Review 8.  Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer.

Authors:  S Nagar; R P Remmel
Journal:  Oncogene       Date:  2006-03-13       Impact factor: 9.867

Review 9.  Inactivation of androgens by UDP-glucuronosyltransferase enzymes in humans.

Authors:  Alain Bélanger; Georges Pelletier; Fernand Labrie; Olivier Barbier; Sarah Chouinard
Journal:  Trends Endocrinol Metab       Date:  2003-12       Impact factor: 12.015

10.  The microRNA.org resource: targets and expression.

Authors:  Doron Betel; Manda Wilson; Aaron Gabow; Debora S Marks; Chris Sander
Journal:  Nucleic Acids Res       Date:  2007-12-23       Impact factor: 16.971

View more
  24 in total

Review 1.  MicroRNA Pharmacoepigenetics: Posttranscriptional Regulation Mechanisms behind Variable Drug Disposition and Strategy to Develop More Effective Therapy.

Authors:  Ai-Ming Yu; Ye Tian; Mei-Juan Tu; Pui Yan Ho; Joseph L Jilek
Journal:  Drug Metab Dispos       Date:  2015-11-13       Impact factor: 3.922

2.  miRNA-324, a potential therapeutic target for paracetamol-induced liver injury.

Authors:  Hong Min Wu; Sang Geon Kim
Journal:  Stem Cell Investig       Date:  2016-10-25

3.  Hepatic expression of transcription factors affecting developmental regulation of UGT1A1 in the Han Chinese population.

Authors:  Ya-Li Nie; Hang He; Jiang-Feng Li; Xiang-Guang Meng; Liang Yan; Pei Wang; Shu-Jie Wang; Hong-Zheng Bi; Li-Rong Zhang; Quan-Cheng Kan
Journal:  Eur J Clin Pharmacol       Date:  2016-10-05       Impact factor: 2.953

Review 4.  The role of microRNAs in hepatocyte metabolism and hepatitis B virus replication.

Authors:  Wanyu Deng; Mengji Lu
Journal:  Virol Sin       Date:  2016-12-28       Impact factor: 4.327

Review 5.  The effects of microRNA on the absorption, distribution, metabolism and excretion of drugs.

Authors:  Y He; J R Chevillet; G Liu; T K Kim; K Wang
Journal:  Br J Pharmacol       Date:  2014-12-01       Impact factor: 8.739

6.  Regulation of UGT2B Expression and Activity by miR-216b-5p in Liver Cancer Cell Lines.

Authors:  Douglas F Dluzen; Aimee K Sutliff; Gang Chen; Christy J W Watson; Faoud T Ishmael; Philip Lazarus
Journal:  J Pharmacol Exp Ther       Date:  2016-07-29       Impact factor: 4.030

7.  Transcriptome association analysis identifies miR-375 as a major determinant of variable acetaminophen glucuronidation by human liver.

Authors:  Ioannis Papageorgiou; Marina Freytsis; Michael H Court
Journal:  Biochem Pharmacol       Date:  2016-08-13       Impact factor: 5.858

8.  GSTZ1 expression and chloride concentrations modulate sensitivity of cancer cells to dichloroacetate.

Authors:  Stephan C Jahn; Mohamed Hassan M Solayman; Ryan J Lorenzo; Taimour Langaee; Peter W Stacpoole; Margaret O James
Journal:  Biochim Biophys Acta       Date:  2016-02-02

9.  Identification and validation of microRNAs directly regulating the UDP-glucuronosyltransferase 1A subfamily enzymes by a functional genomics approach.

Authors:  Ioannis Papageorgiou; Michael H Court
Journal:  Biochem Pharmacol       Date:  2017-04-19       Impact factor: 5.858

10.  Atorvastatin attenuation of ABCB1 expression is mediated by microRNA miR-491-3p in Caco-2 cells.

Authors:  Alice C Rodrigues; Elida Adalgisa Neri; Sidney Veríssimo-Filho; Nancy Amaral Rebouças; Rosario D C Hirata; Ai-Ming Yu
Journal:  Eur J Pharm Sci       Date:  2016-08-26       Impact factor: 4.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.